Pasithea Therapeutics Amends PAS-004 Trial to Add Higher Dose Levels, Extend Treatment

MT Newswires Live06-16

Pasithea Therapeutics (KTTA) amended the protocol for its phase 1/1b trial of PAS-004 in neurofibromatosis type 1 patients with symptomatic inoperable, incompletely resected or recurrent plexiform neurofibromas, the company said Tuesday.

The amended protocol adds higher dose levels of 24 mg and 32 mg, allows evaluation of intermediate doses and extends treatment in the dose-escalation portion of the study to up to 18 months, Pasithea Therapeutics said.

The company has completed enrollment and multi-cycle dosing in the 4 mg, 8 mg, 12 mg and 18 mg cohorts and has enrolled patients in the 15 mg and 24 mg cohorts, it said.

Pasithea Therapeutics said it remains on track to provide an interim update from the trial in Q4.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment